AVR
Delivery · Highdata caveat$1.3B1mo
Anteris Technologies Global Corp
Medical Devices · Cardiac
Structural heart company developing DurAVR, a biomimetic transcatheter aortic valve using proprietary ADAPT tissue technology, currently enrolling the global PARADIGM pivotal trial backed by a strategic partnership with Medtronic.
Data HealthTrials3 of 3 active · stale enrollment
Cash data from Sept 2025 4C(8mo old)Figures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$14.1M
Sept 2025 4C
Runway
1moCRITICAL
Based on Sept 2025 4C
Market Cap
$1.3B
Burn Rate
$30.7M/qtr
Sept 2025 4C
Shares Outstanding
97M
Pipeline Assets
1
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther24 May 2026
Prospectus Supplement and Sales Agreement
Anteris Technologies has established a $250 million at-the-market (ATM) equity offering with TD Securities, allowing the company to sell common stock opportunistically through Nasdaq and ASX. The offering provides capital flexibility for the structural heart company developing its lead DurAVR® transcatheter heart valve product.
3M Price
AVR.ASX$13.050+43.4% 3M
Low $7.300High $13.800
Pipeline Assets (1)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
1 transactionLast 90dNet Buy
Buys1+1 vs prior
Sells0
Buy Value$102k
Catalysts (12)· 7 upcoming · 5 past
Medtronic co-commercialization agreement details
UpcomingExpectedarrow_upwardHigh30 Sept 2026
TCT 2026 DurAVR clinical data presentation
UpcomingConfirmedremoveMed31 Oct 2026
Expectedarrow_upwardHigh31 Dec 2026
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
High83/100(limited data)
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 4 of 4 guided dates· rolling 2yr· of 12 tracked
Filing discipline not scored — this company reports under US regime (Form 10-K / 10-Q). ASX Listing Rule 4.7C deadlines don't apply.
What drove these scores · rolling 2yr
·
Results for the First Quarter of 2026 — Delivered on time
·
Quarterly Results Announcement and SEC Form 10-Q — Delivered on time
·
Prospectus Supplement and Sales Agreement — Delivered on time
·
DurAVR® Transcatheter Heart Valve (THV) ANSM — PARADIGM - French Regulatory Clearance — Delivered on time
·
Limited data adjustment — Score adjusted toward neutral (4/6 data points) — accuracy improves with more completed catalysts
Completed catalysts
✓Results for the First Quarter of 2026— Anteris reported Q1 2026 results with US$320 million capital raise completed in January 2026 to support the PARADIGM Trial. The company advanced patient enrollment across Europe and recently commenced U.S. enrollment, with CMS coverage determination expected to facilitate site adoption and recruitment.
On time
✓Quarterly Results Announcement and SEC Form 10-Q— Anteris Technologies (AVR) filed Q1 2026 quarterly results showing a structural heart medical device company in development stage. Related party payments totaled US$2.3 million during the quarter, comprising director fees and executive compensation. The company remains focused on commercializing its DurAVR® Transcatheter Heart Valve for aortic stenosis treatment.
On time
✓Prospectus Supplement and Sales Agreement— Anteris Technologies has established a $250 million at-the-market (ATM) equity offering with TD Securities, allowing the company to sell common stock opportunistically through Nasdaq and ASX. The offering provides capital flexibility for the structural heart company developing its lead DurAVR® transcatheter heart valve product.
On time
✓DurAVR® Transcatheter Heart Valve (THV) ANSM — PARADIGM - French Regulatory Clearance— Anteris Technologies received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) for the DurAVR® THV global pivotal trial (PARADIGM Trial). This clearance enables patient recruitment to commence at leading centres in France as part of the company's broader clinical and regulatory strategy.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(6)
3 activeClinicalTrials.gov ↗
NARecruitingEnrollment stale · 232d
TAVR with DurAVR® THVTAVR with SAPIEN THV series or the Evolut THV series
A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System
Severe Aortic Stenosis · Valve-in-valve Procedures
RandomizedSingle Blind18 Years+
Primary endpoint Composite of all-cause mortality, all stroke and cardiovascular hospitalization
ENROL1650
no manual snapshots — enter via record_enrollment.py
NAActive Not RecruitingEnrollment stale · 505d
DurAVR™ THV System
DurAVR™ THV EU-EFS
Symptomatic Aortic Stenosis · Severe Aortic Valve Stenosis · Aortic Valve Calcification +2 more
18 Years+
Primary endpoint All-cause mortality or disabling stroke
ENROL40
no manual snapshots — enter via record_enrollment.py
NAActive Not RecruitingEnrollment stale · 1038d
DurAVRTM THV System
Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study
Aortic Stenosis · Symptomatic Aortic Stenosis · Severe Aortic Valve Stenosis +1 more
65 Years+
Primary endpoint All-cause mortality or disabling stroke
ENROL15
no manual snapshots — enter via record_enrollment.py